Check-Cap is a clinical stage medical diagnostics company. Co. has introduced the C-Scan® test designed to detect polyps before they transform into cancer. The disruptive capsule-based screening technology utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. Co.'s C-Scan system is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient's back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon. The CHEK stock yearly return is shown above.
The yearly return on the CHEK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CHEK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|